Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $2.2 million.

  • Mangoceuticals' Gains from Investment Securities rose 127660.12% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 127660.12%. This contributed to the annual value of $156666.0 for FY2024, which is 1132.08% down from last year.
  • As of Q3 2025, Mangoceuticals' Gains from Investment Securities stood at $2.2 million, which was up 127660.12% from $156666.0 recorded in Q2 2025.
  • Over the past 5 years, Mangoceuticals' Gains from Investment Securities peaked at $2.4 million during Q1 2024, and registered a low of $93333.0 during Q3 2023.
  • Over the past 3 years, Mangoceuticals' median Gains from Investment Securities value was $166666.0 (recorded in 2023), while the average stood at $918666.3.
  • Data for Mangoceuticals' Gains from Investment Securities shows a peak YoY increase of 127660.12% (in 2025) and a maximum YoY decrease of 9338.03% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Mangoceuticals' Gains from Investment Securities stood at $176666.0 in 2023, then fell by 11.32% to $156666.0 in 2024, then skyrocketed by 1276.6% to $2.2 million in 2025.
  • Its Gains from Investment Securities was $2.2 million in Q3 2025, compared to $156666.0 in Q2 2025 and $156666.0 in Q1 2025.